Theresa Louise Werner MD
Cancer Genetics/Cancer Risk Assessment, Gynecologic Cancer, Hematologic Oncology
Deputy Director, Huntsman Cancer Institute; Professor, Division of Oncology, Department of Medicine, Adjunct Professor, Department of OB/Gyn, University of Utah
Join to view full profile
1950 Circle of HopeClinic 2BSalt Lake City, UT 84112
Phone+1 801-585-0100
Fax+1 801-585-0721
Dr. Werner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Theresa Werner is a medical oncology specialist based in Salt Lake City, Utah, at the Huntsman Cancer Institute at the University of Utah. She completed her medical education at Indiana University School of Medicine in 2000, followed by a residency and chief residency in Internal Medicine and a fellowship in Hematology and Medical Oncology at the University of Utah School of Medicine. Dr. Werner serves as the Deputy Director at Huntsman Cancer Institute and has subspecialties in gynecologic cancers, cancer genetics, and clinical trials.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2004 - 2007- University of Utah HealthResidency, Internal Medicine, 2000 - 2003
Indiana University School of MedicineClass of 2000
Certifications & Licensure
UT State Medical License 2001 - 2028
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
- Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Publications & Presentations
PubMed
- Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.Paula M Fracasso, Nicole L Simone, Stephanie J Si Lim, Karen L Reckamp, Julie Ann Sosa
JCO Oncology Practice. 2026-07-01 - Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.Maj K Kjeldsen, Frederik Otzen Bagger, Henrik Roed, Gitte-Bettina Nyvang, Charlotte Aaquist Haslund
Translational Oncology. 2026-05-01 - 3 citationsTreatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/mwith advanced ovarian ca...Matthew Savas, Erin Bailey, Erik Harrington, Eleni Gamvroulas, T Joseph Mattingly 2nd
International Journal of Gynecological Cancer. 2025-11-01
Press Mentions
What Are Clinical Trials, and How Do They Work?November 13th, 2025- Community DeathsMarch 16th, 2021
‘Beacon of Hope’: New Ovarian Cancer Drug Improves Survival Rates, Utah Doctors SayOctober 1st, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
